Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.48 |
| ▸ | SQLE | Q14534 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16359707 | 1.00 | KMT2A (0.54) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL795270 | 1.00 | KMT2A (0.54) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL29112065 | 0.83 | KMT2A (0.50) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL811630 | 0.83 | KMT2A (0.45) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL11586065 | 0.82 | KMT2A (0.58) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL356392 | 0.82 | KMT2A (0.58) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL11584608 | 0.82 | KMT2A (0.58) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL8066159 | 0.81 | KMT2A (0.52) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL30990927 | 0.81 | KMT2A (0.58) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL127329 | 0.81 | KMT2A (0.58) | KMT2AMEN1CYP3A4ALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| EP-2616056-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | Neuroquest Inc. (CA) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012034232-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | PMP22, PTGES, GGPS1 | KMT2A 3842/4885MEN1 2728/4885CYP3A4 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.